Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thiocolchicoside is a semisynthetic derivative of colchicoside, itself a glucoside from the Colchicum autumnale plant. It is classified as a muscle relaxant with anti-inflammatory and analgesic properties. Thiocolchicoside is primarily used for the symptomatic treatment of painful muscle spasms associated with musculoskeletal conditions such as acute or chronic back pain, neck pain, postoperative pain, ankylosing spondylitis, rheumatoid arthritis, joint disease, vertebral damage, traumatic injuries, nerve conditions (e.g., persistent torticollis), and other orthopedic or rheumatic disorders[1][2][3][5]. Its mechanism of action involves interaction with gamma-aminobutyric acid type A (GABA-A) receptor and strychnine-sensitive glycine receptor in the central nervous system; it acts mainly as an antagonist at Gamma-aminobutyric acid type A receptor but also exhibits partial agonist-like effects on inhibitory neurotransmission[2][6]. This leads to reduced muscle tone and spasticity. Due to safety concerns including potential genotoxicity and epileptogenic risk (convulsant activity), regulatory agencies have restricted its use to short-term adjuvant therapy for adults[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiocolchicoside.